# Chris Simon

> Chris Simon is the Boston-based president and chief executive officer of Haemonetics. A former U.S. Army infantry officer and McKinsey senior partner, he helped lead Haemonetics’ strategy review before becoming CEO in May 2016. His career also includes Baxter, board service at AdvaMed, and an independent directorship at Sotera Health beginning in August 2024.

- **Role:** President and Chief Executive Officer at Haemonetics
- **Organizations:** Haemonetics, Sotera Health, AdvaMed, McKinsey & Company (former), Baxter Healthcare Corporation (former), U.S. Army (former)
- **Education:** Bachelor of Science in Economics, Wharton School, University of Pennsylvania, MBA, Harvard Business School
- **Known for:** Led the McKinsey strategy review that preceded his appointment as Haemonetics CEO., Led Haemonetics as president and CEO from May 2016 through the research date in October 2026., Chaired AdvaMed’s CEO Roundtable beginning in 2022.

## Career timeline

- **Before 1993** — Served as a U.S. Army infantry officer in Korea and with the 1st Ranger Battalion, and worked in commercial and operating roles at Baxter.
- **1993** — Joined McKinsey & Company; later became a senior partner and leader of its Global Medical Products Practice.
- **2015-10** — Led the McKinsey strategy review for Haemonetics.
- **2016-05-16** — Began as president and CEO of Haemonetics, succeeding interim CEO Ronald Gelbman.
- **2016-09-12** — Elected a director of Haemonetics.
- **2019-12** — Haemonetics opened its downtown Boston headquarters during his tenure.
- **2022** — Began chairing AdvaMed’s CEO Roundtable; subsequently handed the chair to Devdatt Kurdikar.
- **2024-08-01** — Appointed an independent director of Sotera Health and a member of its Leadership Development and Compensation Committee.
- **2025-03** — Haemonetics announced Frank Chan as incoming COO and Roy Galvin as chief commercial officer.

## Achievements

- Led the McKinsey strategy review that preceded his appointment as Haemonetics CEO.
- Led Haemonetics as president and CEO from May 2016 through the research date in October 2026.
- Chaired AdvaMed’s CEO Roundtable beginning in 2022.
- Appointed an independent director of Sotera Health in August 2024.

## Latest updates

- **2026-08** — Haemonetics reported first-quarter fiscal 2027 revenue of $339.4 million, up 5.6 percent year over year, and raised annual guidance.
- **2026-06** — Simon participated in a June 8 investor fireside chat at the Goldman Sachs conference in Miami Beach.

## Links

- Website: https://www.haemonetics.com/about-us/leadership
- LinkedIn: https://www.linkedin.com/in/chrissimon1

---

Profile page: https://yespress.io/chris-simon
Published by YesPress — https://yespress.io
Last updated: 2026-10-22